Data Supplement for Bartels et al., Pragmatic Replication Trial of Health Promotion Coaching for Obesity in Serious Mental Illness and Maintenance of Outcomes. Am J Psychiatry (doi: 10.1176/appi.ajp.2014.14030357)

TABLE S1. Additional Baseline Clinical Characteristics of Participants in the In SHAPE and Fitness Club Membership Groups^a

	Total Sample (N=210)		Fitness Club Membership (N=106)		In SHAPE (N=104)	
Characteristic	N	%	N	%	N	%
Weight in lbs (M±SD)	235.4±54.1		238.9±57.9		231.8±50.1	
Body Mass Index (M±SD)	36.8±8.2		37.5±8.8		36.2±7.5	
Obese (BMI≥30)	166	79	82	77	84	81
Very Severely Obese (BMI≥40)	65	31	36	34	29	28
Waist circumference in inches (M±SD)	46.9±7.2		47.8±7.5		46.0±6.7	
Average number of psychotropic medications (M±SD)	2.05±1.10		1.92±1.10		2.06±1.08	
Use of medications with high weight gain propensity ^b	54	26	20	22	29	33
Use of medications with medium weight gain propensity ^c	88	42	49	46	39	38
Use of medications with low weight gain propensity ^d	46	22	27	26	19	18
Risk of Hypertension ^e	81	39	42	40	39	38
Systolic Blood Pressure (M±SD)	130.17±19.14		131.97±17.70		128.39±20.40	
Elevated Systolic Blood Pressure ^f	62	30	32	30	30	29
Diastolic Blood Pressure (M±SD)	81.88±12.03		84.13±10.93		79.65±12.69	
Elevated Diastolic Blood Pressure ^g	49	23	25	24	24	23
Total Cholesterol (M±SD)	174.88±46.50		179.02±48.71		170.64±43.96	
Elevated Total Cholesterol ^h	60	29	31	29	29	28
HDL (M±SD)	43.72±15.84		44.55±16.02		42.88±15.68	
Low HDL ⁱ	125	60	61	58	64	62
LDL (M±SD)	100.85±36.83		104.94±35.80		96.76±37.59	
Elevated LDL ^j	39	19	22	21	17	16
Triglycerides (M±SD)	163.94±112.65		161.85±113.81		166.05±111.98	
Elevated Triglycerides ^k	87	41	43	41	44	42

^aMeans were compared by t tests, and proportions were compared by chi square tests.

^bHigh weight gain propensity medications include: olanzapine, clozapine

^cMedium weight gain propensity medications include: haloperidol, risperidone, quetiapine, thioridazine, chlorpromazine, paroxetine, amitriptyline, divalproex, valproate, doxepin, lithium, carbamazepine, imipramine, gabapentin

^dLow weight gain propensity medications include: ziprasidone, perphenazine, fluphenazine, fluoxetine, buproprion, venlafaxine, molindone, lamotrigine, duloxetine, aripiprazole, fluvoxamine, trazodone, desipramine, loxapine, sertraline, escitalopram, clomipramine, nortriptyline, citalopram, paliperidone, topiramate, mirtazapine, lurasidone ^eRisk of hypertension was defined as systolic > 140 and diastolic > 90

fElevated systolic blood pressure was defined as > 140

gElevated diastolic blood pressure was defined as > 90

^hElevated cholesterol was defined as total cholesterol ≥ 200

ⁱLow HDL was defined as ≤ 40 in women and ≤ 50 in men

^jElevated LDL was defined as ≥ 130

^kElevated triglycerides was defined as ≥ 150

TABLE S2. Maintenance of Primary Weight and Fitness Outcomes, and Secondary Outcomes Between In SHAPE and Fitness Club Membership (FCM) Groups From 12 to 18 Months

Outcome	Group	12-Month		18-Month		Group by Time Effect (12-18 Months) ^a		
		М	SD	М	SD	df	F	р
Primary Weight and Fitness Outcomes								
Weight (lbs.)	In SHAPE	226.5	48.8	228.7	53.0	1, 145	.608	.437
	FCM	239.6	61.9	234.1	62.4			
Cardiorespiratory Fitness 6 MWT Distance (feet)	In SHAPE	1385.3	275.4	1307.4	269.9	1, 133	2.605	.109
	FCM	1247.3	319.4	1239.4	258.9			
Secondary Outcomes								
ВМІ	In SHAPE	35.0	7.1	35.5	7.7	1, 145	.850	.358
	FCM	37.4	9.6	36.5	9.4			
Waist Circumference (inches)	In SHAPE	44.3	6.6	44.1	7.1	1, 147	.724	.396
	FCM	46.1	7.6	44.6	7.7			
Exercise Minutes	In SHAPE	99.8	135.0	130.2	204.3	1, 161	.623	.431
	FCM	148.9	224.3	124.6	250.8			
IPAQ Total Vigorous Score	In SHAPE	379.8	890.8	331.7	1110.5	1, 167	.220	.640
(Log of MET min)	FCM	433.7	1080.1	382.2	1938.4			
Readiness to Change Dietary Behaviors	In SHAPE	3.7	0.7	3.6	0.6	1, 154	5.150	.025
	FCM	3.4	0.6	3.6	0.6			
Secondary Dietary Behavior Outcomes								
Total calories ^b	In SHAPE	1893	907	1704	835	1, 143	.111	.740
	FCM	1787	967	1681	839			
% calories fat ^b	In SHAPE	37.9	7.6	36.6	7.3	1, 147	.028	.867
	FCM	36.8	7.9	35.9	8.2			
% calories sweets ^b	In SHAPE	9.7	10.8	12.1	13.1	1, 149	1.177	.280
	FCM	9.7	10.0	9.8	11.6			
Fruit servings/day ^b	In SHAPE	1.3	0.9	1.2	1.0	1, 140	.043	.836
	FCM	1.3	1.0	1.2	1.0			
	1		l .	1	<u> </u>	l	1	

Veg.	_							
servings/day ^b	In SHAPE	3.6	2.8	3.0	2.6	1, 138	3.408	.067
	FCM	3.3	3.4	3.7	4.0			
Secondary Blood								
Pressure and								
Serum Lipid								
Outcomes								
Systolic Blood	In SHAPE	130.6	17.3	135.1	22.9	1, 157	.526	.469
Pressure	III SIIAI E	130.0	17.5	155.1	22.5	1, 137	.520	.405
	FCM	130.3	18.2	132.5	18.9			
Diastolic Blood Pressure	In SHAPE	80.0	12.2	83.1	15.2	1, 154	7.718	.006
	FCM	84.4	11.4	80.7	11.9			
Total Cholesterol	In SHAPE	166.3	42.8	165.3	40.0	1, 151	.018	.894
	FCM	172.9	42.7	174.4	43.2			
HDL	In SHAPE	49.2	17.2	50.5	19.2	1, 148	.123	.726
	FCM	48.4	17.2	51.5	20.2			
LDL	In SHAPE	89.8	34.9	88.6	30.6	1, 130	.115	.735
	FCM	96.8	34.8	94.3	33.3			
Triglycerides	In SHAPE	156.1	108.0	156.1	94.3	1, 154	.399	.528
	FCM	158.3	103.9	144.5	97.7			

^aMeans shown in table consist of raw (unadjusted) means. ^bBlock Food Frequency Questionnaire

FIGURE S1. Study CONSORT Diagram

